Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.01
+6.0%		$0.01
$0.01
▼
$7.89
$478K0.13651,670 shs28,530 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.00
$0.04
$0.00
▼
$0.33
$274K0.736,316 shs3,774 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.02
-4.3%		$0.06
$0.02
▼
$6.66
$388K0.09221,592 shs64,111 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
+6.00%+6.00%+6.00%-39.43%-99.87%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%-58.82%-96.50%-96.50%-98.55%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-4.33%-10.53%-62.29%-77.88%-99.33%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
$0.01
+6.0%		$0.01
$0.01
▼
$7.89
$478K0.13651,670 shs28,530 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.00
$0.04
$0.00
▼
$0.33
$274K0.736,316 shs3,774 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.02
-4.3%		$0.06
$0.02
▼
$6.66
$388K0.09221,592 shs64,111 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
+6.00%+6.00%+6.00%-39.43%-99.87%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%-58.82%-96.50%-96.50%-98.55%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-4.33%-10.53%-62.29%-77.88%-99.33%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
1.67
Reduce$30.00282,918.87% Upside
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.00
SellN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/A($41.98) per shareN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.08N/AN/A$2.46 per share0.01
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$12.05M0.01$1.61 per share0.02($0.37) per share-0.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
-$8.30M-$9.84N/AN/AN/AN/AN/A-209.40%9/2/2026 (Estimated)
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$1.68N/AN/AN/AN/AN/A-479.36%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$2.25N/AN/AN/A-825.01%-482.05%-88.90%11/5/2026 (Estimated)
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
-$3.59M$3.730.01N/AN/AN/A-237.65%57.29%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
N/A
0.56
0.56
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/A
0.66
0.66

Institutional Ownership

CompanyInstitutional Ownership
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
29.64%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
11.61%

Insider Ownership

CompanyInsider Ownership
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
0.36%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
5.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
CERo Therapeutics Holdings, Inc. stock logo
CERO
CERo Therapeutics
845.11 million1.05 millionN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A130.60 million40.29 millionNot Optionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13017.57 million5.44 millionNo Data
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
203.41 million3.23 millionNo Data

Recent News About These Companies

TRACON Pharma (OTC:TCON) Stock, Short Interest Report
October 5, 2024  |  benzinga.comhttps://www.benzinga.com/quote/TCON/short-interest
TRACON Pharmaceuticals Announces it Will Wind Down Operations
July 30, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/07/30/2921433/10391/en/tracon-pharmaceuticals-announces-it-will-wind-down-operations.html
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
June 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/11/2896712/10391/en/tracon-announces-publication-in-clinical-cancer-research-of-phase-2-clinical-data-for-trc102-a-dna-damage-repair-inhibitor-in-recurrent-glioblastoma-patients.html
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock Price Settled at $1.49: What’s Resulting?
May 27, 2024  |  bovnews.comB
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call Transcript
May 15, 2024  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/tracon-pharmaceuticals-inc-nasdaqtcon-q1-2024-earnings-call-transcript/ar-BB1mqOyK
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/q1-2024-tracon-pharmaceuticals-inc-105310624.html?.tsrc=rss
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tracon-pharmaceuticals-inc-tcon-q1-071015646.html?.tsrc=rss
TCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024
May 14, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/05/tcon-stock-earnings-tracon-pharma-for-q1-of-2024/?utm_source=Tradesmith&utm_medium=referral
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tracon-pharmaceuticals-reports-first-quarter-200100042.html
Tracon: Q1 Earnings Snapshot
May 14, 2024  |  timesunion.comT
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/14/2881830/10391/en/tracon-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-update.html
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 7, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/07/2877173/10391/en/tracon-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-on-may-14-2024.html
TRACON Pharmaceuticals Inc
April 26, 2024  |  money.usnews.comhttps://money.usnews.com/investing/stocks/tcon-tracon-pharmaceuticals-inc/vitals
Buy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation Update
April 10, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-reaffirmed-for-tracon-pharmaceuticals-post-reverse-split-and-envafolimab-valuation-update-1033238463
TRACON announces 1-for-20 reverse stock split
April 10, 2024  |  uk.investing.comhttps://uk.investing.com/news/stock-market-news/tracon-announces-1for20-reverse-stock-split-93CH-3422554
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
April 10, 2024  |  investorplace.comhttps://investorplace.com/2024/04/wall-street-favorites-3-penny-stocks-with-strong-buy-ratings-for-april-2024/
Shares of Tracon Pharmaceuticals Tumble 22% on Reverse Split
April 8, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/shares-of-tracon-pharmaceuticals-tumble-22-on-reverse-split-997bdc19
TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock Split
April 8, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-04/61890558-tracon-pharmaceuticals-inc-tracon-pharmaceuticals-announces-reverse-stock-split-399.htm
TRACON Pharmaceuticals Announces Reverse Stock Split
April 8, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/08/2859242/10391/en/tracon-pharmaceuticals-announces-reverse-stock-split.html
Buy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial Outlook
April 4, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-affirmed-for-tracon-pharmaceuticals-amid-promising-envafolimab-trial-outlook-1033220294

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERo Therapeutics stock logo

CERo Therapeutics NASDAQ:CERO

$0.01 +0.00 (+6.00%)
As of 08/28/2026 01:13 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.0021 0.00 (0.00%)
As of 08/27/2026 03:14 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.02 0.00 (-4.33%)
As of 08/28/2026 03:48 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

TRACON Pharmaceuticals stock logo

TRACON Pharmaceuticals NASDAQ:TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas